中国医学科学院学报

高级检索
中国医学科学院学报

中国医学科学院学报 ›› 2011, Vol. 33 ›› Issue (2): 123-126.doi: 10.3881/j.issn.1000-503X.2011.02.005

• 综述 • 上一篇    下一篇

重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症的安全性问题

舒 畅, 潘 慧   

  1. 中国医学科学院 北京协和医学院 北京协和医院内分泌科,北京100730
  • 收稿日期:2011-02-16 出版日期:2011-04-10 发布日期:2011-04-10
  • 通讯作者: 潘慧 电话:010-65295815 E-mail:ph3610@gmail.com

Safety of Recombinant Human Growth Hormone in Treating Children with Growth Hormone Deficiency and Idiopathic Short Stature

SHU Chang, PAN Hui   

  1. Department of Endocrinology, PUMC Hospital, CAMS and PUMC, Beijing 100730,China
  • Received:2011-02-16 Online:2011-04-10 Published:2011-04-10
  • Contact: PAN Hui Tel:010-65295815 E-mail:ph3610@gmail.com

摘要: 重组人生长激素的安全性总体较好,但也有少量不良反应出现,如水钠潴留、良性颅内高压、胰岛素敏感性下降、继发肿瘤发生的危险性升高、脊柱侧凸、股骨头滑脱等,但总体发生率较低。

关键词: 重组人生长激素, 生长激素缺乏症, 特发性矮小, 不良反应

Abstract: Recombinant human growth hormone is generally safe in treating children with growth hormone deficiency and idiopathic short stature. However, side effects such as sodium and water retention, benign intracranial hypertension, insulin insensitivity, increasing risk of secondary neoplasm, scoliosis, and slipped capital femoral epiphysis may occur occasionally, although the overall incidence remains low.

Key words: recombinant human growth hormone, growth hormone deficiency, idiopathic short stature, adverse drug reactions

中图分类号: